Bristol-Myers Squibb (BMY) said on Friday it will take a pre-tax charge of $1.8 billion in the third quarter related to the scrapping of a highly-anticipated hepatitis C drug trial earlier this month after one of its study patients died of heart failure.

The New York-based company, which disclosed of the impairment charge in a regulatory filing on Friday morning, said it does not expect to incur further costs related to the study. 

The pharmaceutical giant voluntarily stopped the mid-stage trial of the drug BMS-986094 earlier this month “in the interest of patient safety” after one of the study’s patients died and several others were hospitalized.

Bristol had acquired the drug through its $2.5 billion February purchase of Inhibitex.

The impairment charge will likely be recorded as a one-time cost when Bristol reports third-quarter earnings later this year. 

Shares of the company were up just under 1% to $32.37 in relatively light trade.

Follow Jennifer Booton on Twitter at @Jbooton